Cyrano Therapeutics is a biotechnology company focused on the development of therapeutics for diseases of the nose and sinuses. The company's lead product candidate is aimed at addressing chronic rhinosinusitis, a condition that affects millions of people worldwide.

Cyrano Therapeutics has developed a unique, proprietary intranasal formulation to restore function in patients with a chronic loss of taste and smell.  This is a condition affecting more than 40 million people in the US and Europe and millions more across the world, having a significant impact on safety, quality of life and well-being.  Currently no marketed pharmaceutical therapy exists and aside from the Cyrano product, none are in the pipeline.
 
The Cyrano formulation (CYR-064) has been tested with success in a 92 patient pilot study and the Company is currently enrolling patients in a Phase 2 placebo-controlled double-blind randomized trial at 14 sites in the United States with data readout expected in Q1'25.

Additional information can be found on our website www.cyranotherapeutics.com





 


COM:CYRANOTHERAPEUTICS

Cyrano Therapeutics

Analysis Not Available